What one analyst characterized as a "weird" placebo response in one patient was enough to skew the results for Rigel Pharmaceuticals Inc.'s second of two double-blind studies in its FIT phase III program with fostamatinib, an oral spleen tyrosine kinase inhibitor, in adults with chronic/persistent immune thrombocytopenia (ITP).